Aastrom Biosciences ends drug trial, to cut half its workforce

Aastrom Biosciences ends drug trial, to cut half its workforce

March 27, 2013 9:09 am by | 0 Comments

(Reuters) – Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia – a form of peripheral arterial disease – and cut about half of its workforce.
The company now plans to focus on its experimental tre…


Stanford docs may be too cozy with drug companies (Morning Read)

Stanford docs may be too cozy with drug companies (Morning Read)

December 20, 2010 8:43 am by | 0 Comments

As medical schools wrestle with how to keep drug companies from corrupting their faculties, Stanford University often is lauded for its tough stance. But a ProPublica investigation found that more than a dozen of the school’s doctors were



Cardiovascular cell therapy firm Aastrom expands partnership with ATEK Medical

Cardiovascular cell therapy firm Aastrom expands partnership with ATEK Medical

October 27, 2010 8:35 pm by | 0 Comments

“We expect that this collaboration will be a critical advantage for Aastrom as we move our cardiovascular programs into the final stages of clinical development,” said Aastrom CEO Tim Mayleben in prepared remarks.


Nashville’s medical trade center good for economy (Morning Read)

Nashville’s medical trade center good for economy (Morning Read)

October 19, 2010 8:46 am by | 0 Comments

Forty-four percent of the people who took a poll by the Nashville Business Journal think their city’s medical trade center project is key for economic development so it should get state tax credits to draw tenants.


Q&A: Aastrom Biosciences’ CEO Tim Mayleben

Q&A: Aastrom Biosciences’ CEO Tim Mayleben

April 14, 2010 10:56 am by | 2 Comments

Tim Mayleben had a front-row seat as a board member to the shaky period two years ago when stem cell company Aastrom Biosciences was clinging to survival. Now, he’s in…


Aastrom finishes treating patients in Phase 2 heart failure trial

Aastrom finishes treating patients in Phase 2 heart failure trial

March 9, 2010 12:19 pm by | 0 Comments

Aastrom Biosciences Inc. has finished treating patients in a Phase 2 clinical trial of its cardiac-repair stem cells. The milestone clears the way for Aastrom to report six-month interim results…


Aastrom Biosciences is back in Nasdaq’s good graces

Aastrom Biosciences is back in Nasdaq’s good graces

March 5, 2010 10:09 am by | 0 Comments

Aastrom Biosciences, once in danger of being deslisted from the Nasdaq, has regained compliance with the stock exchange’s $1 minimum share price requirement. In December, the stem cell company was…



Aastrom Biosciences looks to begin Phase 3 trial of vascular-repair stem cells

Aastrom Biosciences looks to begin Phase 3 trial of vascular-repair stem cells

February 24, 2010 11:28 am by | 0 Comments

Stem cell company Aastrom Biosciences plans to begin a Phase 3 clinical trial of its treatment for critical limb ischemia. Critical limb ischemia results from a decreased blood supply, is…


Michigan stem cell company Aastrom Biosciences completes 1-for-8 reverse split

Michigan stem cell company Aastrom Biosciences completes 1-for-8 reverse split

February 18, 2010 1:48 pm by | 0 Comments

Aastrom Biosciences Inc. has completed a 1-for-8 reverse stock split that has so far achieved its desired effect–pushing the company’s share price above $1 so it can remain listed on the Nasdaq stock exchange.


Michigan’s Aastrom Biosciences announces reverse stock split; shares plummet

Michigan’s Aastrom Biosciences announces reverse stock split; shares plummet

February 9, 2010 12:06 pm by | 0 Comments

Stem cell company Aastrom Biosciences announced an 8-for-1 reverse stock split in an attempt to avoid being delisted by the Nasdaq stock exchange.


Michigan’s Aastrom Biosciences prices stock offering, shares tumble to 52-week low

Michigan’s Aastrom Biosciences prices stock offering, shares tumble to 52-week low

January 15, 2010 2:20 pm by | 0 Comments

Aastrom, which is developing therapies that use stem cells to treat cardiovascular diseases, priced its shares at 26 cents per unit and hopes to raise $10.9 million from the offering.


Michigan early stage venture firm Arboretum adds former Aastrom Biosciences CEO

Michigan early stage venture firm Arboretum adds former Aastrom Biosciences CEO

January 8, 2010 11:38 am by | 0 Comments

Early stage health investor Arboretum Ventures has added George Dunbar, former chief executive of Michigan biotech company Aastrom Biosciences Inc., as a partner.